Rocket Pharmaceuticals, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| 9IP1.F | LXEO | SLDB | TNYA | RNA | RGNX | |
|---|---|---|---|---|---|---|
| Market cap | 241.50M | 265.14M | 699.11M | 84.31M | 148.48M | 508.96M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -0.9 | -2.4 | -3.8 | -0.9 | -1.5 | -2.6 |
| Price/book | 0.7 | 1.1 | 2.9 | 1.2 | 0.7 | 5.8 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −19.40% | −62.07% | +54.69% | −73.91% | −41.15% | −30.98% |
| Today | −2.22% | +3.86% | +3.82% | +2.66% | −0.46% | +1.05% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All 9IP1.F news ›Rocket Pharmaceuticals Presents Preliminary Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy at 28th Annual Meeting of the American Society of Gene and Cell Therapy
RP-A601 was generally well-tolerated at a dose of 8.0E13 GC/kg with no dose-limiting toxicities in all three patients with up to 12 months follow-up Improvement or stabilization observed in arrhythmia burden, heart function, and quality of…
Rocket Pharmaceuticals to Participate in Chardan’s 10th Annual Healthcare Conference
For more information about Rocket, please visit www.rocketpharma.com and follow us on LinkedIn, YouTube, and X. These forward-looking statements include, but are not limited to, statements concerning Rocket’s planned participation in the…
Rocket Pharmaceuticals enters up to $150M loan deal
Ericsson reports third quarter results 2026 Rocket said existing resources and the initial draw are expected to fund planned operations into the third quarter of 2028. Rocket Pharmaceuticals entered a senior secured term-loan facility with…
Cranbury biotech Rocket Pharmaceuticals lands credit facility for up to $150M from Hercules Capital
Gaurav Shah, M.D. - Rocket Pharmaceuticals Rocket Pharmaceuticals Inc., a biotechnology company advancing genetic medicines for rare and life-threatening diseases, announced Oct. 7 that it has entered into a credit facility agreement with…
More from 1 other outlet
Rocket Pharmaceuticals, Inc. (RCKT) Discusses Danon Disease Program Update With Focus on RP-A501 Pivotal Trial and Preliminary Clinical Data Transcript
Rocket Pharmaceuticals, Inc. (RCKT) Discusses Danon Disease Program Update With Focus on RP-A501 Pivotal Trial and Preliminary Clinical Data October 6, 2026 4:30 PM EDT Meg Dodge - Senior Vice President & Head of External AffairsGaurav…
Rocket Pharmaceuticals Announces Positive Clinical Safety Update from Initial Three Patients Treated with RP-A501 Under Modified Phase 2 Protocol for Danon Disease
Initial three patients were treated safely; RP-A501 was well-tolerated with no TMA or capillary leak syndrome observed Rocket is actively engaging with the FDA to align on the path to pivotal trial completion; regulatory pathway update…
Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Keeps Outperform Rating at Wedbush
Wedbush reiterated their outperform rating on shares of Rocket Pharmaceuticals (NASDAQ:RCKT – Free Report) in a research note published on Wednesday,Benzinga reports. View Our Latest Stock Report on RCKT Here are the key news stories…
More from 1 other outlet
Rocket Pharmaceuticals (NASDAQ:RCKT) Earns Buy Rating from Chardan Capital
Rocket Pharmaceuticals (NASDAQ:RCKT – Get Free Report)‘s stock had its “buy” rating reiterated by stock analysts at Chardan Capital in a research report issued on Wednesday, Benzinga reports. They presently have a $11.00 target price on…
Rocket Pharmaceuticals Details RP-A501 Pivotal Plan After Safety Reset
Chief Executive Officer Gaurav Shah said the company’s existing resources and an initial $35 million funding under a new Hercules facility are expected to support operations into the third quarter of 2028. Subject to borrowing conditions,…
Transcript : Rocket Pharmaceuticals, Inc. - Special Call
Presentation Operator MessageOperator Good day, and welcome to the Rocket Pharmaceuticals Investor Program Update on Danon disease and the RP-A501 pivotal Phase II trial. As a reminder, today's... Transcript : Rocket Pharmaceuticals, Inc.…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- marketscreener.com15
- defenseworld.net5
- stocktitan.net4
- abfjournal.com1
- gurufocus.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 30 articles, not a forecast.